secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ultragenyx Pharmaceutical Inc. (RARE)
CIK:        0001515673
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0000950170-25-074529
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ultragenyx shareholders approve amended incentive plan, elect directors, ratify auditor
--------------------------------------------------------------------------------

- Stockholders approved Second Amended and Restated 2023 Incentive Plan, authorizing up to 11.5M new shares plus forfeited shares from prior plans.
- Class III directors Matthew K. Fust and Amrit Ray, M.D. elected to Board for term expiring 2028.
- Advisory vote on executive compensation received 55.1M for (68%) vs 26.1M against.
- Ernst & Young ratified as fiscal 2025 independent auditor with 84.3M votes for.
- Broker non-votes of 5.3M shares on director election, incentive plan, and say-on-pay proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025074529/0000950170-25-074529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1515673/000095017025074529/rare-20250515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-074529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer